Loading…
5 companies · GEL, thousands · columns ordered by revenue
Only 2 of 5 peers filed FY2024. Switch to FY2021 (4 of 5).
| Line item | Pip Company | Med Parmasi Group | Sando Pharma | Medimex | Grasse Pharma Georgia |
|---|---|---|---|---|---|
| Total Revenue | 1,276 | 1,185 | — | — | — |
| Total COGS | -1,174 | -752 | — | — | — |
| Gross Profit | 102 | 433 | — | — | — |
| Gross Margin | 8.0% | 36.5% | — | — | — |
| Total Operating Expenses | -301 | -444 | — | — | — |
| EBITDA | -198 | -11 | — | — | — |
| EBITDA Margin | -15.5% | -0.9% | — | — | — |
| Total D&A | -1 | -61 | — | — | — |
| EBIT / Operating Income | -199 | -72 | — | — | — |
| Total Other Income | -110 | -32 | — | — | — |
| Profit Before Tax | -309 | -105 | — | — | — |
| Total Income Tax | 0 | 0 | — | — | — |
| Net Profit / (Loss) | -309 | -48 | — | — | — |
| Net Margin | -24.2% | -4.1% | — | — | — |
Not every picked company reports every selected year — FY2024: 3 of 5 companies have no filing. Those cells are left blank (no filing), not zero.
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Med Parmasi Group | Pharma | -0.9% | 14th pct | 110 |
| Pip Company | Pharma | -15.5% | 3rd pct | 110 |
| Sando Pharma | Pharma | — | no FY data | 110 |
| Medimex | Pharma | — | no FY data | 110 |
| Grasse Pharma Georgia | Pharma | — | no FY data | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.